Skip to main content
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
269.42
-1.09 (-0.40%)
Mar 28, 2025, 7:22 PM BST

Alnylam Pharmaceuticals Revenue

In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B USD with 22.97% growth. Alnylam Pharmaceuticals had revenue of $593.17M in the quarter ending December 31, 2024, with 34.90% growth.

Revenue
$2.25B
Revenue Growth
+22.97%
P/S Ratio
n/a
Revenue / Employee
$1.01M
Employees
2,230
Market Cap
26.85B GBP

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 43.19B
GSK plc 31.38B
Haleon 11.23B
Smith & Nephew 4.64B
ConvaTec Group 1.83B
Hikma Pharmaceuticals 2.50B
HUTCHMED (China) 503.39M
Genus 671.60M
Revenue Rankings

Alnylam Pharmaceuticals News

More News